null John Storring, MD, CM
Myelodysplastic syndrome • leukemia • clinical trials • quality of life
My research focuses on the treatment of bone marrow cancers. in particular the leukemias and myelodysplastic syndrome. I am the local lead investigator on several national and international studies in hematologic malignancy. Additionally, in conjunction with other Canadian centres we are building a registry of patients with myelodysplastic syndrome that will offer insights into how these patients are managed in Canada, the outcomes of their treatments and their qualty of life.
Seftel MD, Serebrin A, Lambert P, Bergeron J, Everett J, Kew A, Jones D, Meloche C, Paulson K, Sabloff M, Sharif I, Storring J, Turner D Acute Promyelocytic Leukaemia is Characterized by Stable Incidence and Improved Survival that is Restricted to Patients Managed in Leukaemia Referral Centres: A Pan-Canadian Analysis Br J Haematol. 2014 Apr 30.
Yee KWL, Storring JM, Buckstein R, Wells R, Xenocostas A, Kovacs MJ, Howson-Jan K, Wang ES, Battista K, Wang L, Oza A, Ivy SP, Schuh AC Sunitinib malate in patients with intermediate-2 or high-risk myelodysplastic syndrome or chronic myelomonocytic leukemia. Leuk Lymphoma. 2014 Apr 22.
Wells RA, Leber B, Zhu NY, Storring JM. Optimizing outcomes with azacitidine: recommendations from Canadian centres of excellence. Curr Oncol. 2014 Feb;21(1):44-50.
Brandwein JM, Geddes M, Kassis J, Kew AK, Leber B, Nevill T, Sabloff M, Sandhu I, Schuh AC, Storring JM, Ashkenas J. Treatment of older patients with acute myeloid leukemia (AML): a Canadian consensus. Am J Blood Res. 2013 May 5;3(2):141-64.
Leitch HA, Buckstein R, Shamy A, Storring JM. The immunomodulatory agents lenalidomide and thalidomide for the treatment of myelodysplastic syndromes: A clinical practice guideline. Crit Rev Oncol Hematol 2013 Feb;85(2):162-92.